drugset

drugset / Trial / NCT01792310

A Phase 1/2A Study of LAM561 in Adult Patients With Advanced Solid Tumours

NCT01792310 ↗

Phase 1/2 Completed 54 enrolled Laminar Pharmaceuticals Instituto Oncológico IMQ, Clínica IMQ Zorrotzaurre. Bilbao · collab Northern Institute for Cancer Research, Newcastle · collab Onkologikoa, San Sebastián. · collab Royal Marsden NHS Foundation Trust · collab Specialized Medical Services (SMS)-Oncology BV · collab Vall d'Hebron Institute of Oncology · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a phase 1/2A, open label, non-randomized study in patients with advanced solid tumours including malignant glioma

Timeline

Start: 2013-05
Primary completion: 2016-09
Completion: 2016-09

Publications

Lopez J, Lai-Kwon J, Molife R, Welsh L, Tunariu N, Roda D, Fernandez-Garcia P, Llado V, McNicholl AG, Rossello CA, Taylor RJ, Azaro A, Rodon J, Sludden J, Veal GJ, Plummer R, Urruticoechea A, Lahuerta A, Mujika K, Escriba PV. A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma. Br J Cancer. 2023 Sep;129(5):811-818. doi: 10.1038/s41416-023-02356-1. Epub 2023 Jul 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LAM561	Small molecule	250 mg	Oral
Subject	LAM561	Small molecule	500 mg	Oral
Subject	LAM561	Small molecule	1 g	Oral
Subject	LAM561	Small molecule	2 g	Oral
Subject	LAM561	Small molecule	4 g	Oral
Subject	LAM561	Small molecule	8 g	Oral

Indications